Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Quick Listen: Scrip’s Five Must-Know Things

Executive Summary

Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.

This episode includes insights from around the biopharma world for the business week ended 22 January 2021.

This time we have more from JPM including mid-term launch plans from a UK major and how successful the virtual format was, contingency plans for a single-dose coronavirus vaccine, an antibody for COVID-19, and a roundup of the industry’s own views of its prospects for the coming year.

Scrip Podcasts Now On Spotify!

Listen to the latest industry news, analysis and opinion from our editorial team on Spotify.
Listen on Spotify

These and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Play, SoundCloud and TuneIn - and now on Spotify Podcasts - and also via smart speakers if one of these channels has been set up as your default podcast provider. 

Stories mentioned in this episode:

(Also see "GSK Aims To Launch 13 Blockbusters In Five Years" - Scrip, 18 Jan, 2021.)

(Also see "J.P. Morgan, Without The Parties, Reveals An Industry Ready To Get Down To Business" - Scrip, 14 Jan, 2021.)

(Also see "J&J Has A Plan B If Gamechanger Single Dose Vaccine Disappoints" - Scrip, 15 Jan, 2021.)

(Also see "Humanigen Takes Aim At IL-6 Inhibitors With CRS Drug Lenzilumab" - Scrip, 20 Jan, 2021.)

(Also see "Scrip Asks…What Does 2021 Hold For Biopharma? Part 1: Tackling COVID-19" - Scrip, 18 Jan, 2021.)


Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts